Gilead Sciences, Inc (NASDAQ:GILD) shares traded 1.15% higher at $114.54 on Wall Street last session.
GILD stock price is now 6.67% away from the 50-day moving average and 14.99% away from the 200-day moving average. The market capitalization of the company currently stands at $142.48B.
On March 04, 2025, Oppenheimer reiterated its ‘Outperform’ rating on the stock by increasing its target price from $115 to quote $132, while ‘Deutsche Bank’ rates the stock as ‘Buy’
In other news, O’Day Daniel Patrick, Chairman & CEO sold 10,000 shares of the company’s stock on Jun 30 ’25. The stock was sold for $1,104,484 at an average price of $110.45. Upon completion of the transaction, the Chairman & CEO now directly owns 615,725 shares in the company, valued at $70.53 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 30 ’25, Officer DANIEL O’DAY bought 10,000 shares of the business’s stock. A total of $1,104,483 was incurred on buying the stock at an average price of $110.45. A total of 0.16% of the company’s stock is owned by insiders.
During the past 12 months, Gilead Sciences, Inc has had a low of $67.65 and a high of $119.96. As of last week, the company has a debt-to-equity ratio of 1.30, a current ratio of 1.37, and a quick ratio of 1.23. According to the stock market information, the enterprise value for the company is $154071416832, which is based on a 24.08 price-to-earnings ratio, a 0.92 price-to-earnings-growth ratio, and a beta of 0.35. The fifty day moving average price for GILD is $107.373 and a two-hundred day moving average price translates $99.6093 for the stock.
The latest earnings results from Gilead Sciences, Inc (NASDAQ: GILD) was released for 2025-03-31. The net profit margin was 20.79% and return on equity was 32.51% for GILD. The company reported revenue of $6.67 billion for the quarter, compared to $6.69 billion a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -0.28 percent.
